MEDIGENE AG (MDG1.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:MDG1 - DE000A40ESG2 - Common Stock
MDG1.DE Key Statistics, Chart & Performance
The current stock price of MDG1.DE is 0.1335 EUR. In the past month the price decreased by -91.1%. In the past year, price decreased by -91.36%.
MDG1.DE Technical Analysis
MDG1.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MDG1.DE. The financial health of MDG1.DE is average, but there are quite some concerns on its profitability.
MDG1.DE Financial Highlights
Over the last trailing twelve months MDG1.DE reported a non-GAAP Earnings per Share(EPS) of -1.25. The EPS decreased by -94.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -56.15% | ||
| ROE | -82.28% | ||
| Debt/Equity | 0.08 |
MDG1.DE Forecast & Estimates
8 analysts have analysed MDG1.DE and the average price target is 3.88 EUR. This implies a price increase of 2803.37% is expected in the next year compared to the current price of 0.1335.
For the next year, analysts expect an EPS growth of 38.46% and a revenue growth 100% for MDG1.DE
MDG1.DE Ownership
About MDG1.DE
Company Profile
MediGene AG is a biotechnology company, which engages in developing innovative, complementary treatment platforms that target various types and stages of cancer. The company is headquartered in Planegg, Bayern and currently employs 86 full-time employees. The company went IPO on 2000-06-30. The firm focuses on the development of personalized T cell-based immunotherapies. The company develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors. The firm operates offices in Martinsried in Germany, as well as in Washington DC and San Diego in the United States.
Company Info
MEDIGENE AG
Lochhamer Strasse 11
Planegg BAYERN DE
Employees: 87
Phone: 49892000330
MEDIGENE AG / MDG1.DE FAQ
What does MEDIGENE AG do?
MediGene AG is a biotechnology company, which engages in developing innovative, complementary treatment platforms that target various types and stages of cancer. The company is headquartered in Planegg, Bayern and currently employs 86 full-time employees. The company went IPO on 2000-06-30. The firm focuses on the development of personalized T cell-based immunotherapies. The company develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors. The firm operates offices in Martinsried in Germany, as well as in Washington DC and San Diego in the United States.
What is the current price of MDG1 stock?
The current stock price of MDG1.DE is 0.1335 EUR. The price decreased by -27.64% in the last trading session.
Does MEDIGENE AG pay dividends?
MDG1.DE does not pay a dividend.
What is the ChartMill technical and fundamental rating of MDG1 stock?
MDG1.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists MDG1 stock?
MDG1.DE stock is listed on the Frankfurt Stock Exchange exchange.
What is the expected growth for MDG1 stock?
The Revenue of MEDIGENE AG (MDG1.DE) is expected to grow by 100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.